Table 1.

A summary of topics with published meta-analyses.

KRAS

KRAS mutations have a negative prognostic impact on overall survival and recurrence-free survival [18]. Patients with KRAS-mutated CRLM benefit from anatomic resections [33]. The prognostic role of primary tumor laterality is dependent on KRAS mutational status [24].

BRAF

BRAF mutations have a negative prognostic impact on overall survival and recurrence-free survival [38,41,42]. The risk of both intrahepatic and extrahepatic recurrence is significantly higher in patients with BRAF mutations [38].